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Results: Single treatments with either anti-PD-1 checkpoint-
blocking or CD133-specific T cell-recruiting antibodies had 
only very little effect on tumor growth. Hypofractionated 
tumor irradiation alone delayed tumor growth more strongly, 
but also only transiently for about 2 weeks. Hypofractionated 
tumor irradiation induced tumor-specific effector T cells. In 
accordance with this, the double combination of local 
radiotherapy and anti-PD-1 antibody caused long-lasting 
tumor regressions including some complete cures, even in 
mice with large melanomas. Moreover, the cured mice 
remained immune to subsequent rechallenge with rather high 
doses of either CD133+ or CD133– B16 melanoma cells. 
Noteworthy effects were also observed upon administration 
of the bispecific T cell-recruiting antibody into mice with 
irradiated tumors. The underlying mechanisms of these 
observations will be presented at the meeting. 
Conclusions: The study suggests that the evaluation of 
potential synergistic radiotherapy/immunotherapy 
combinations in immunocompetent mouse tumor models can 
provide crucial information for clinical trial planning. 
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High-tech solutions desperately looking for problems, or are 
we really making a difference?  
“Modern radiation oncology is a well-established, cost-
effective and essential component in the curative and 
palliative treatment of malignancy.” A statement no one can 
argue with. The challenge of individualized treatment 
optimization continuously drives research and technology, 
yet we should be careful not to get trapped in the “Cargo 
Cult Science” as described by Richard Feynman. In this 
lecture, the author - coming from a radiotherapy department 
with in its banner the vision: “to offer the optimal and most 
efficient radiation therapy tailored to the individual patient, 
through development and clinical implementation of novel 
irradiation techniques” - takes a critical view on new 
technologies in radiation oncology. New developments are 
more likely to be adopted if they improve the workflow, and 
if the benefits are more favourable, or at least equal to 
current care. However, sometimes it seems as if we are in a 
blind gallop towards increasingly more precise means of 
tumour localization and irradiation, the perception being 
that it is largely driven by vendors rather than the care 
takers’ or patients’ needs. If development moves too fast, 
the focus might be too strong on the innovation itself and less 
on the (safe) implementation. Industry funded research 
doesn’t help much, in that less favourable results do not 
always end up being published, hence inducing a strong bias 
towards a perception that improved treatment delivery 
requires high-tech solutions; whereas sometimes common 
sense might yield equivalent clinical results. Scientific and 
technological progress comes at a significant cost, and many 
concerns exist regarding the value of that progress. Within 
the current state of the economy, health care politicians face 
the difficult challenge to allow progress through efficacy and 
driven by outcomes. What’s even worse is the danger that 
too much focus on sophisticated expensive technology may 
create a double layer health care system where not all 
patients have access to the best of care. In the end what 
counts is the result, not how we got there. Does this mean 
we have to refrain from innovation? Certainly not. Indeed, 
looking back at the technological progress that has been 
realized the last decades (perhaps “century” is more apt), 
this evolution has been translated successfully into clinical 
improvements both in patient cure as well as quality of life 
(with recent developments such as IMRT, IGRT, BCRT, IGBT, 
SBRT, IMPT, etc, as a proof of concept). In conclusion, it is 
safe to state that many good technological solutions are 
being developed as we speak, the challenge is to introduce 
these innovations adapted to the radiotherapy requirements 
(the end-users) … not the other way around. 
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Human papillomavirus (HPV) infections are an essential cause 
for virtually all carcinomas of the uterine cervix and subsets 
of other anogenital, oropharyngeal and laryngeal tumors. The 
HPV aetiological contribution differs in each anatomical 
location reflecting differences in natural history and viral 
tissue tropism. Up to 99,9% of cervical, 80% of anal and 30% 
of vulvar cancers have been defined as HPV DNA positive by 
epidemiological studies. In the head-and-neck (H&N) region, 
HPV DNA positivity was detected in up to 50% of 
oropharyngeal (in Central Europe) and 35% of laryngeal 
cancers. However, recent studies on H&N cancers 
(specifically oropharyngeal cancer/cancer of the tonsil) have 
demonstrated that the presence of HPV DNA per se in 
invasive tumor tissues is insufficient proof for viral causality 
and could result in misclassification of malignant lesions and 
consequently, mistreatment of cancer patients. In addition, 
several studies have reported a better response to 
radiotherapy of HPV-driven oropharyngeal carcinomas, but 
not non-HPV-driven ones. Therefore, defining HPV-driven 
tumors by measuring markers of HPV-transformation in 
addition to HPV DNA, is crucial. Cervical squamous cell 
carcinoma (CSCC) is the best-understood model for HPV-
transformation, and up to 99% of HPV DNA positive CSSC are 
also HPV-driven. In addition to HPV DNA presence, CSCC is 
characterized by: (i) at least 1 viral genome copy present in 
each tumor cell (viral load), (ii) expression of viral oncogenes 
E6 and E7 (HPV RNA), and (iii) alteration of steady state 
levels of cellular proteins, most consistently up-regulation of 
p16INK4a. Outside of the cervix, this proof-of-principle marker 
combinations have been, to various extents, demonstrated 
for the cancer of the oropharynx, larynx, vulva and anus, 
with HPV16 being a leading transforming agent. In Central 
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Europe approximated fraction of HPV-driven oropharyngeal 
cancers is 25%, and laryngeal cancers only 5%, versus 50% and 
35% suggested by HPV DNA studies for these anatomical sites, 
respectively. The use/usefulness of specific markers and 
marker combinations to define an HPV-driven tumor will be 
discussed. 
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The recent understanding of mechanisms of HPV-induced 
carcinogenesis has lead to the development of prophylactic 
vaccines, however radiotherapy still remains a major therapy 
in HPV-related cancer and despite concurrent chemotherapy, 
the outcome remains suboptimal. Therefore, improving the 
radiotherapeutic index remains an important challenge as 
well as defining predictive assays for treatment outcome of 
HPV-related tumours. Elucidating the influence of the HPV 
virus on tumour radiosensitivity is of major interest. There is 
several lines of evidence showing that head and neck HPV-
positive tumours have better outcome compared to non HPV 
related tumours and given the role of HPV oncoproteins on 
tumor immunity, it is possible that the feature of immune 
and microenvironmental factors during radiation response 
could be specific to HPV related tumors. Genetic feature of 
HPV+ cervical cancer has also been investigated and 3q gain 
has been shown to be particularly frequent in cervical 
cancers infected with the HPV16 virus type (84%) as well as in 
oropharyngeal and lung cancers. Other cancers such as anal 
and penile cancers are caused by or at least are associated 
with HPV infection. HPV-associated malignancies have 
common molecular feature, however specific response can 
also be expected and interfere with response to radiotherapy 
such as the contribution of organ-specific microbiota. In any 
case, investigating radiation response in this various type of 
cancer would help to decipher the role of HPV in radiation 
sensitivity and assess whether HPV+ cancer cells are 
intrinsically more sensitive to radiotherapy; or if HPV+ 
tumors release upon radiotherapy immunogenic viral proteins 
that promote tumor clearance and may prevent 
recurrence.This difference may allow for different 
combination of treatment strategies to be developed.  
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Approximately 5% of all cancers worldwide are considered 
attributable to Human papillomavirus (HPV) and as such HPV 
associated cancers constitute a significant global disease 
burden. A causal relationship between HPV and cervical 
cancer was established almost 40 years ago and HPV is 
necessary for the development of cervical cancers, of which 
more than 99% harbour virus. Detection rates of HPV at other 
ano-genital sites (vulva, vagina and anus) are somewhat 
lower (65-80%), and clinical data suggest that outcome at 
these sites differ significantly dependent on the HPV-status 
of the tumors, in a way that patients with HPV-positive 
tumors have better prognosis compared to HPV-negative 
patients. 
In head and neck cancer (HNSCC), tobacco and alcohol were 
until recently considered to be the major risk factors for 
carcinogenesis. However, the putative role of HPV in HNSCC 
has been investigated since the 1980s, and at present 
sufficient molecular and pathological evidence exists to 
etiologically link HPV to a subset of HNSCCs. The strongest 
association with HPV is found in oropharynx cancer (OPC) 
where tumors of the tonsils are particularly associated with 
HPV infection, but high-risk HPV, predominantly HPV-16, has 
been found in HNSCC from all sites although with a 
significantly higher prevalence in OPC compared to tumors 
arising outside the oropharyngeal region (non-OPC).  
Numerous clinical studies have demonstrated a highly 
significant impact of tumour HPV/p16-status on radiotherapy 
(RT) outcome in advanced OPC where the influence of tumor 
HPV/p16-status seems indisputable. These observations are 
believed to be caused in part by a higher sensitivity of 
HPV/p16-positive tumors to RT, combined with a different 
and more favourable risk factor profile (including less heavy 
tobacco history) and better general health status in the group 
of patients with HPV/p16-positive disease. Less is known 
about the influence of HPV/p16-status in non-OPC and 
clinical data published so far have reached different 
conclusions. Data based on a rather large cohort of patients 
with advanced larynx and hypopharynx cancer treated with 
primary (chemo)radiotherapy suggested that the prognostic 
impact of HPV/p16-status does not extend to tumors of non-
oropharyngeal origin. The reasons for this apparent site-
specific difference in the prognostic impact of HPV/p16-
status in HNSCC remain unsolved and warrant further 
investigation. 
Presently there is substantial variation in the treatment 
strategies considered for patients with head and neck cancer 
dependent of the HPV/p16-status of the tumors. Some 
clinical trials are investigating whether de-intensified 
treatment strategies could result in avoidance of excessive 
toxicity without compromising outcome for selected patients 
with “low-risk” HPV/p16-positive OPC. At the opposite end of 
the spectrum other trials are investigating whether additional 
intensification of treatment could be beneficial for patients 
with HPV/p16-negative HNSCC based on their observed poor 
outcome, in order to secure optimal and safe treatment for 
these patients also. 
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Purpose/Objective: Etiologic role of Human Papilloma Virus 
(HPV) in cervical cancer is well established. Radio (chemo) 
therapy remains the mainstay of treatment. Response, 
relapses & overall outcome and correlation with HPV is not 
well known. With an aim to study this we undertook this 
study. 
Materials and Methods: After Institutional Ethical clearance 
and obtaining written informed consent patients were invited 
to participate in this prospective observational study. 
Patients who were treated with radio (chemo) therapy for 
cervical cancer underwent quantitative estimation of HPV 16 
and 18 viral load pre treatment, at treatment completion, 2 
and 5 months post treatment on cervical biopsies/ brushings 
using polymerase chain reaction (PCR). The viral load were 
compiled, evaluated and correlated with standard clinical 
response evaluation. 
